Skip to main content

Table 2 Summary of clinical findings

From: CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer

Parameter

No. of patients

%

Response* (n = 71)

  

  Pathologic complete response

7

9.9

  Clinical complete response

4

5.6

  Partial response

22

31.0

  Stable disease

33

46.5

  Progressive disease

5

7.0

Symptom relief (n = 53)

  

  Complete relief

30

56.6

  Partial relief

17

32.1

  No relief

6

11.3

  1. *: 14 patients underwent radical resections (R0) post-chemoradiation.